BPH OVERVIEW / MANAGEMENT. Richard L Haddad Norwest Private Hospital 17 Oct 2018
|
|
- August Anthony
- 5 years ago
- Views:
Transcription
1 BPH OVERVIEW / MANAGEMENT Richard L Haddad Norwest Private Hospital 17 Oct 2018
2 Introduction Learning outcomes; Develop a management plan for BPH patients Describe the new medical therapies in BPH and discuss their place in treatment. 230,000 GP visits, Australia, per annum Autopsy data incidence; >50% AGE 50, >75% AGE 80
3 Pathogenesis 1 1. Stromal hyperplasia 2. Glandular hyperplasia 3. Compressed peripheral zone 4. Peri-urethral compression 5. Dynamic smooth muscle hypertonia
4 Pathogenesis 2 Bladder wall pressure structural dysfunction
5 Pathogenesis 3 1. Cell proliferation vs. Apoptosis 2. Local androgen environment 3. Pro-inflammatory growth factors 4. Testis derived growth factor 5. Genetic imprinting of prostate cells pre-puberty 6. Inheritable; Odds ratio 4x 1st degree relative / 3x Father / 8x Brother 7. DHT, intracellular conversion from T, by 5AR 8. DHT has a Potent affinity for AR 9. Increased. BCL2 gene = anti-apoptotic 10. Dormant stem cell activation
6 Clinical Presentations of BPH Early minor LUTS Progressive bothersome LUTS / Failed medical therapy PV; 20-25gm / 60gm / >100gm / gm UTI Haematospermia Haematuria +/- Bladder cancer concomitant Elevated PSA / Prostate cancer Urinary retention ULTRASOUND; bladder stone, bladder diverticulum, High PVR, Middle lobe, Chronic prostatitis / pelvic pain syndrome Difficult catheterisation; ward or intra-operatively Neurological conditions; CVA, DM, pelvic surgery, spinal injury, spinal disc prolapse Detrusor Instability vs Detrusor Underactivity **Comorbidities & Anaesthetic Risk, Anticoagulants
7 Differential Diagnoses of LUTS ** DIABETES AUTONOMIC NEUROPATHY
8 GP Assessment AJGP VOL. 47, NO. 7, JULY 2018 History; Voiding & storage symptoms Urethral stricture Haematuria UTI / STI Prostatitis / pelvic pain Urinary retention Nocturnal polyuria (Cardiac, OSA) DM, Bladder cancer, Spinal dx, Pelvic surgery, Medication (diuretics) Focused PE; DRE Palpable bladder Non-circumcised / phimosis IDC
9 GP Investigations MSU PSA - risk of BPH progression Prostate cancer Response to 5ARI / TURP MRI / Biopsy Pvol. PVR Bladder tumour Middle lobe
10 GP Assessment Summary GP History; LUTS, PMH, meds, FHx prostate Focused Physical Exam DRE U/A MSU PSA EUC Ultrasound Urologist IPSS / Bother score IIEF DRE PSA EUC MSU U/S Urine cytology Flow study Cystoscopy Urodynamics MRI Prostate Biopsy
11
12
13
14 Principles of Treatment Based on symptom severity & bother; IPSS <7, IPSS 8-18, IPSS Treatment is NOT recommended in minor LUTS or low bother (AUA) At risk of BPH progression; Age >60, Pvol. >30gm, Qmax <12ml/s, Identifiable LUTS, PSA >1.4
15 Alpha-blockers Uro-selective; Tamsulosin, Alfuzosin, Doxazosin, Terazosin DO NOT alter BPH progression ie. retention, surgery, Pvol. Side Effects; RG ejaculation, floppy iris syndrome (cataract), postural hypotension, nasal congestion
16 5 alpha Reductase Inhibitor Dutasteride (type 1&2), Finasteride (type 1) Alters BPH progression; 30% volume shrinkage Reduces PSA by 50% Reduces risk surgery and retention Inidcations; PSA > 1.5, Haematuria, Large prostate >40cc ED, loss libido, gynaecomastia, increased risk HG cap
17 BJUI, 2018, population based study Confrims; 5-ARI DOES increase risk GS 8-10 cancer Increases risk by 20-25% (low absolute risk 0.5%) NO increase in prostate cancer mortality Initial 2 RCT NEJM 2003, 2010 Reasons; 1. Easier detection / Artefactual due to glandular cytoreduction 2. Detection bias, men with LUTS are more likely to have CaP investigations If PSA rises whilst on 5ARI, need cancer investigation
18 Combination therapy Alpha blocker + 5-ARI GP can commence Duodart Better IPPS/flow outcomes vs. monotherapy alone PV >40cc, age >50, PSA >1.5 Increased sexual dysfn. than monotherapy alone
19 n=4844 Tamsulosin 400mcgm Dutasteride 0.5mg Combination Combination therapy best Reduced RR; AUR, BPH surgery Most effective PV>40gm Dutasteride-effect
20 Antimuscarinics & beta-3 agonists Urgency, frequency, nocturia MECHANISM; detrusor smooth muscle relaxation & increased bladder storage capacity Oxybutinin - Ditropan, M1,2,3 cholinergic receptor antagonist Solifenacin - Vesicare, M3 cholinergic receptor antagonist Tolterodine - Detrusitol, M2,3 cholinergic receptor antagonist (*bladder specific) Mirabegron - Betmiga, Beta3 adrenergic agonist, *Better tolerability CAUTION; High PVR >200ml, Elderly SIDE EFFECTS; dry mouth, dry eyes, constipation, confusion, drug interact. (QT)
21 PDE5I phosphodiesterase inhibitors High level evidence for Both BPH + ED Tadalafil 5mg, Cialis, longer t(1/2) Improves IPPS storage and voiding symptoms Mechanisms; increased cellular cgmp reduces smooth muscle tone - detrusor urethra prostate Increased NO increases blood oxygenation to LUT
22 Desmopressin Synthetic analogue ADH / vasopressin Reduces urine production Nocturnal polyuria (time/vol. chart) in elderly with Cardiac dx or OSA, can co-exist with BPH Reduces nocturnal voids and increases hours of undisturbed sleep Hyponatraemia - Na+ monitoring baseline, day 4, day 30
23 Phytotherapies NOT recommended in major guidelines Plant based Saw palmetto (Serenoa repens) African plum bark, (Pygeum africanum) Cochrane = placebo effect Lack consistent pharmacokinetics
24 Indications for Surgery Moderate to severe LUTS & Bother Failed medical therapy Urinary retention; recurrent Bladder calculi Recurrent UTI & High PVR Recurrent clots /haematuria Renal dysfunction Bladder diverticulum
25 Surgical Options TURP (Bipolar vs Monopolar) Laser prostatectomy Greenlight Photoselective Vaporisation PVP 180XPS HoLEP holmium laser enucleation Diode laser vaporisation Thulium laser Plasma button bipolar plasma kinetic vaporisation BNI - Bladder neck incision Open enucleative prostatectomy MINIMALLY INVASIVE TECHNIQUES (MIT); TMUT - transurethral microwave therapy TUNA - transurethral needle ablation UROLIFT - Prostatic urethral lift REZUM - Convective water vapour energy ablation PAE - Prostatic artery embolisation
26 Surgical algorithm
27 Risks of surgery RG ejaculation, 53-75% ED, 3-30% incontinence, 2% urethral stricture, 2-9% BN contracture, 3% sepsis (MSU) bleeding capsular perforation
28 Surgical issues Surgeon vs. Patient preferences Established data Lasers and anticoagulant Aspirin and TURP is ok Experimental; Rezum, PAE Emerging; Urolift
29 Urodynamics 1990 s [1] Uroflow [2] Filling phase [3] Voiding phase Meta-analysis evidence Obstructed Detrusor instability / reduced compliance (CVA Parkinson s MS) Underactive bladder (DM spinal cord/disc pelvic surgery) Mixed symptoms
30 10 studies n= month f/up Suture-based implants, retraction of lateral lobes No resection or ablation >50yr, IPSS>12, Qmax<12ml/s, Pvol.20-80gm Exclusion; median lobe, pvol.>80gm, retention>250ml Less RG ejac/ed than TURP Outcomes; IPSS 7pts, Qmax 3-4ml/s, QOL 2pts
31 Convective water vapour + RF current (thermal)? Reduced risk ejaculatory & ED & MIT / day procedure Disposable consumable cost to patient $2000 Bias / Company; Rezūm System (NxThera Inc., Maple Grove, MN, USA) US FDA clearance ml water vapour injected for 9sec, overlapping zones, circumferentially <24 month clinical data 2 weeks for symptom improvement Majority need IDC 3 days and still irritation post procedure Suitability;? Unclear suitable Pvol.? median lobe Claimed benefits; IPSS & Qmax Re-treatment rate, Treatment failures? True rates DURABILITY is unknown
32 Super-selective radiological prostatic arterial embolisation / infarction No Level 1 RCT evidence ROPE study ( ) n=216 PAE, 89 TURP Claim = reduce IPSS 12 pts Not as good as TURP Suitable; older patient, >100cc, lateral lobe adenoma, no middle lobe, unfit for GA Outpatient day procedure Excluded; Heavily calcified internal iliac artery Re-treatment 20% at 12 months, arterial dissection, sepsis
33 n=25, mean Pvol. 150gm 77-85% improvements in Qmax, IPSS, PVR Mean operative time = 214 min. Mean hospital stay 4 days
Male Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon
Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationEAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (Text update March 2017) S. Gravas (Chair), T. Bach, M. Drake, M. Gacci, C. Gratzke, T.R.W. Herrmann, S. Madersbacher,
More informationBenign Prostatic Hyperplasia: Update on Innovative Current Treatments
Benign Prostatic Hyperplasia: Update on Innovative Current Treatments Michael Ferrandino, MD As.soc Professor Director of Minimally Invasive Urologic Surgery Division of Urologic Surgery Duke University
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationEAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (Limited text update March 2016) S. Gravas (Chair), T. Bach, A. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher,
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (Text update March 2015) S. Gravas (Chair), T. Bach,. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (BPO)
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (BPO) (Text update pril 2014) S. Gravas (chair),. Bachmann,. Descazeaud, M. Drake, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationWhat is Benign Prostatic Hyperplasia (BPH)?
What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationConsensus Meeting for Asian-Pacific BPH Guideline
Consensus Meeting for Asian-Pacific BPH Guideline Byung Ha Chung Yonsei University Health System S a t e l l i t e S y m p o s i u m I Contents Diagnosis and Treatment Guidelines for BPH Prostate Volume
More informationCase studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES
Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationBPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG FECSM Beaconsfield Medical Practice, Brighton & Brighton & Sussex Universities NHS Trust As man draws near the common goal Can anything be sadder Than he
More informationRezūm procedure for the Prostate
Rezūm procedure for the Prostate Mr Jas Kalsi Consultant Urological Surgeon This booklet has been provided to help answer the questions you may have with regards to your enlarged prostate and the Rezūm
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses TABLE OF CONTENTS INTRODUCTION... 3 WATCHFUL WAITING... 11 STUDY OUTCOMES... 11 MEDICAL THERAPIES... 13 ALPHA-ADRENERGIC ANTAGONISTS (ALPHA-BLOCKERS)...
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Medical technology guidance SCOPE The UroLift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia 1
More informationAN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION
AN OVERVIEW OF THE MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC OBSTRUCTION *Richard Christian Rowan Nayar, Hashim Hashim Continence and Urodynamics Unit, Bristol Urological Institute,
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationWhat can the primary care physician do? Brian W. Ellis
What can the primary care physician do? Brian W. Ellis Consultant Urological Surgeon at Ashford & St Peter s 1983-2007 Currently Consultant Urological Surgeon at Cobham Hospital Visiting Professor at Middlesex
More informationManagement of male LUTS in general practice
17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationManagement of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005
Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationProstate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต
Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common
More informationChapter 2: Methodology
Chapter 2: Methodology TABLE OF CONTENTS Introduction... 2 Study Selection and Data Abstraction... 2 Data Synthesis... 8 Guideline Development and Approvals... 9 Conflict of Interest... 10 Copyright 2010
More informationPolicy for Prostatism/Lower Urinary Tract Symptoms in men
NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical
More informationClinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97
Lower urinary tract symptoms in men: management Clinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transurethral water vapour ablation for lower urinary tract symptoms caused by
More informationLUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital
LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital LUTS- Classification Men LUTS can be divided into: Storage Voiding Frequency Nocturia Urgency
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationFrank P. Begun, M.D. Associate Professor, Urology
Benign Prostate Disorders Frank P. Begun, M.D. Associate Professor, Urology Medical Director, Urological Services at OSU East Hospital The Ohio State University Objectives/Goals To understand the causes
More informationProstate Artery Embolization: A Minimally Invasive Option for the Treatment of BPH
Prostate Artery Embolization: A Minimally Invasive Option for the Treatment of BPH Farrah J. Wolf, MD Diagnostic Radiology, Board Certified Vascular & Interventional Radiology fwolf@bocaradiology.com Educational
More informationProstate Artery Embolization
Prostate Artery Embolization in the office interventional suite Robert J. Kennedy, M.D. Interventional & Vascular Center Melbourne, Florida The speaker has no financial conflicts of interest to disclose.
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases
Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases LUTS/Benign Prostate Hyperplasia Objectives 1. List the lower urinary tract symptoms (LUTS) found in men with BPH. 2. List the differential
More informationPROSTATE ENLARGEMENT A GUIDE TO URINARY SYMPTOMS IN MEN A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM
PROSTATE ENLARGEMENT A GUIDE TO URINARY SYMPTOMS IN MEN A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM AT A GLANCE First published in March 2004 by Andrology Australia 5th
More informationThe Prostate and Its Challenges LUTS in the Aging Male
The Prostate and Its Challenges LUTS in the Aging Male HJ Rayala, MD/PhD Urologic Surgeon, Cambridge Health Alliance Instructor, Harvard Medical School Financial Disclosures Spouse Torque Pharma Employee/Stock
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationLUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group
LUTS in the modern era Dr Jon Rees Tyntesfield Medical Group In the past! Man with urinary symptoms = PROSTATISM Prostatism = TURP TURP unsuccessful = REDO TURP Redo TURP unsuccessful = can t help you!
More informationRezum: A New Non Invasive Promise for Benign Prostate Hyperplasia Treatment
Human Journals Review Article November 2018 Vol.:13, Issue:4 All rights are reserved by Babitha. M et al. Rezum: A New Non Invasive Promise for Benign Prostate Hyperplasia Treatment Keywords: BPH, LUTS,
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationInformation for Patients. Benign Prostatic Enlargement. English
Information for Patients Benign Prostatic Enlargement English Table of contents What is the prostate?... 3 What are BPH, BPE, and BPO?... 3 Symptoms... 3 Types of symptoms... 4 Diagnosis... 4 Medical history...
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms
More informationWednesday 25 June Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario
Wednesday 25 June 14.30 15.30 Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario P080 Unreliable residual volume measurement after increased water load diuresis G. ALIVIZATOS, A. SKOLARIKOS,
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationBenign prostatic hyperplasia (BPH)
Diseases and Conditions Benign prostatic hyperplasia (BPH) By Mayo Clinic Staff Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate
More informationCanadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update
ORIGINAL CUA GUIDELINE RESEARCH Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update J. Curtis Nickel, MD 1 ; Lorne Aaron,
More informationProstatic Urethral Lift
Prostatic Urethral Lift Policy Number: 7.01.151 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Prostatic
More informationR. Matthew Smith M.D. Mercy Urology
R. Matthew Smith M.D. Mercy Urology None Disclosures Goals Update growth of Mercy Urology Clinic Quick Review of Hematuria and PSA Present common urologic complaints seen by the primary care physician
More informationLUTforum Highlights Christian Gratzke LMU Munich
LUTforum Highlights 2015 Christian Gratzke LMU Munich What is LUTforum? Web-based platform to provide specialists with highlights in functional urology presented at major urological congresses PowerPoint
More informationManaging lower urinary tract symptoms in men
Managing lower urinary tract symptoms in men MacKenzie KR, Aning JJ. Managing lower urinary tract symptoms in men. Practitioner 6; 6(79):-6 Mr Kenneth R MacKenzie MBChB MRCS (Ed) Core Trainee in Urology
More informationNON-Neurogenic Chronic Urinary Retention AUA White Paper
NON-Neurogenic Chronic Urinary Retention AUA White Paper Great Lakes SUNA Inside Urology March 16, 2018 Michelle J. Lajiness FNP-BC Nurse Practitioner DMC Urology Incidence Really unknown Lack consensus
More informationLUTS & Cancer pathway. Mr Francis Thomas Urology Consultant DRI &BDGH
LUTS & Cancer pathway Mr Francis Thomas Urology Consultant DRI &BDGH Topics Male and female LUTS Urinary retention Post void Residual urine Referral pathway LUTS Raised PSA Hematuria Services in community
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses Introduction To determine the appropriateness of individual therapies, as well as to develop practice recommendations, the American Urological Association
More informationWorkshop : Managing Urinary Stones and BPH
Workshop : Managing Urinary Stones and BPH How common are they? lifetime risk 15% men, 6% women Dr John Tuckey Urologist Auckland 105 new stones /100,000 peak age incidence 30-50 males 2.3:1 How common
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of transurethral water jet ablation for lower urinary tract symptoms caused by benign
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Prostatic Urethral Lift Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prostatic Urethral Lift Professional Institutional Original Effective Date:
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationSystematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert
More informationThe management of lower urinary tract symptoms in men
The management of lower urinary tract symptoms in men NICE guideline Draft for consultation, August 2009 If you wish to comment on this version of the guideline, please be aware that all the supporting
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationLower Urinary Tract Symptoms
Advances in the management of BPH/LUTS Greetings from the Executive and Members of the European Association of Urology Christopher Chapple Professor of Urology Sheffield Hallam University Consultant Urological
More information10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University
Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University 1. Explain the pathophysiology of benign prostatic hyperplasia (BPH),
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationGENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options
GENDER HEALTH Benign Prostatic Hyperplasia Medical and Surgical Treatment Options ABSTRACT Benign prostatic hyperplasia (BPH) affects the aging male. Treatment options vary widely. Some men will elect
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationMedical technologies guidance Published: 16 September 2015 nice.org.uk/guidance/mtg26
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Medical technologies guidance Published: 16 September 2015 nice.org.uk/guidance/mtg26 NICE 2018. All rights reserved. Subject
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationSurgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE
1 Approved by the AUA Board of Directors May 2018 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2018 by the American Urological
More informationProstatic Urethral Lift. Summary
Section: Surgery Effective Date: January 15, 2017 Subject: Prostatic Urethral Lift Page: 1 of 10 Last Review Status/Date: December 2016 Prostatic Urethral Lift Summary Benign prostatic hyperplasia (BPH)
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More information